CMV disease and overall mortality in the first 180 days after allogeneic SCT among patients who received preemptive treatment for CMV infection with either foscarnet or ganciclovir
| . | Foscarnet n = 110 . | Ganciclovir n = 103 . |
|---|---|---|
| Patients with CMV disease | 5 | 5 |
| Type of CMV disease | ||
| Pneumonia | 3 | 23-150 |
| Gastrointestinal | 2 | 2 |
| Retinitis | 0 | 1 |
| Median time to CMV disease, d (range) | ||
| From SCT | 62 (50-177) | 93 (43-168) |
| From randomized treatment start | 31 (8-126) | 42 (3-128) |
| Overall mortality (%) | 29 (26) | 23 (22) |
| Median time from SCT to death from any cause, d (range) | 118 (39-179) | 85 (43-155) |
| . | Foscarnet n = 110 . | Ganciclovir n = 103 . |
|---|---|---|
| Patients with CMV disease | 5 | 5 |
| Type of CMV disease | ||
| Pneumonia | 3 | 23-150 |
| Gastrointestinal | 2 | 2 |
| Retinitis | 0 | 1 |
| Median time to CMV disease, d (range) | ||
| From SCT | 62 (50-177) | 93 (43-168) |
| From randomized treatment start | 31 (8-126) | 42 (3-128) |
| Overall mortality (%) | 29 (26) | 23 (22) |
| Median time from SCT to death from any cause, d (range) | 118 (39-179) | 85 (43-155) |
CMV indicates cytomegalovirus; SCT, stem cell transplantation.
Fatal in both cases.